Tempus announces strategic collaboration with Janssen


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Tempus announces strategic collaboration with Janssen
This collaboration will help both the companies utilize their respective strengths to improve patient care

Tempus, a leader in artificial intelligence (AI) and precision medicine, announced a strategic collaboration with Janssen Research & Development, LLC, in which Tempus will work closely with Janssen data scientists and oncologists focused on oncology clinical development programs. The collaboration is part of a multi-year data agreement, which is facilitating predictive AI/machine learning projects, as well as Janssen’s participation in Tempus’ TIME Trial Network to accelerate patient enrollment in select biomarker-driven trials. The collaboration will leverage the full capabilities of Tempus with those of Janssen with the intent of bringing the power of precision medicine to address the needs of cancer patients.

As part of the collaboration, Tempus is developing a predictive model using machine learning techniques to enhance enrollment in Janssen’s biomarker-driven clinical trials. The goal is to more rapidly identify patients with specific tumour features to increase the efficiency of clinical trial enrollment, an example of the practical application of AI that can identify the right patient for the right clinical trial at the point-of-care, and ultimately may improve patient outcomes.

In addition, Janssen has joined The TIME Trial Network, Tempus’ clinical trial program which brings clinical trials to communities across the country, offering patients access to novel therapies under development. Several of Janssen’s oncology trials are already leveraging the program, joining a portfolio of over 50 clinical trials and 50 provider networks that are part of Tempus’ network. As part of the program, Tempus screens thousands of patients weekly against each trial’s criteria, matching patients and rapidly activating sites to enroll patients in clinical studies based on their eligibility in as few as 10 days.

“Janssen is the ideal collaborator for this kind of forward-thinking collaboration, in which both companies utilize their respective strengths to improve patient care,” said Ryan Fukushima, Chief Operating Officer of Tempus. “We are harnessing the power of AI and data to deliver patients more personalized therapeutics faster.”

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Tags : #Tempus #LatestNewsonTempus3rdNov #Janssen #LatestNewsonJanssen3rdNov #LatestPharmaCollaboration3rdNov #LatestPharmaNews3rdNov #TIMETrialNetwork #CancerPatients #RyanFukushima

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026